hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06324071, orgStudyIdInfo id: 2022_TSOD_125, briefTitle: Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-08, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Fitoplancton Marino, S.L., class: INDUSTRY, collaborators name: Fundacio Clinic Barcelona, collaborators name: Fertypharm, descriptionModule briefSummary: TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). In a previous pilot trial, the ability of TetraSOD® (dose: 250 mg/day) to improve semen characteristics in idiopathic infertile men after three months of treatment was assessed, revealing significant improvements in almost all of the analyzed parameters. In a further clinical trial close to finish (ClinicalTrials.gov Identifier: NCT04864314) using the same dose, such positive results have been tested again in a higher number of patients, and additional parameters have been included in order to gain insights into the sperm physiological changes that underpin the improvement in semen quality. In this new clinical trial, an intermediate dose (125 mg/day) is going to be tested in an attempt to determine a range of TetraSOD® dosage being clinically active for the treatment of male infertility., conditionsModule conditions: Male Infertility, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Sham, interventions name: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity, outcomesModule primaryOutcomes measure: Sperm motility, primaryOutcomes measure: Sperm concentration, primaryOutcomes measure: Sperm oxidative stress, secondaryOutcomes measure: DNA integrity, secondaryOutcomes measure: sORP by MiOXSYS, secondaryOutcomes measure: Adverse effects, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hospital Clinic, status: RECRUITING, city: Barcelona, zip: 08036, country: Spain, contacts name: Juan M Corral, role: CONTACT, phone: +34 932275545, email: jmcorral@clinic.cat, contacts name: Meritxell Jodar, role: CONTACT, phone: +34 932275510, email: mjodar@clinic.cat, contacts name: Marta Guimerà, role: SUB_INVESTIGATOR, contacts name: Juan M Mayorga-Torres, role: SUB_INVESTIGATOR, contacts name: Antonio Alcaraz, role: SUB_INVESTIGATOR, contacts name: Dolors Manau, role: SUB_INVESTIGATOR, contacts name: Rafael Oliva, role: SUB_INVESTIGATOR, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06324058, orgStudyIdInfo id: Huashan_H, briefTitle: Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-03-18, completionDateStruct date: 2026-03-18, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Huashan Hospital, class: OTHER, descriptionModule briefSummary: This trial plans to enroll 190 eligible patients and randomize them into two groups with a 1:1 ratio, with 95 patients in each group. The experimental group will receive immediate cryoablation therapy at the resection site after TUR, while the control group will only undergo TUR and receive conventional BCG instillation therapy postoperatively. Both groups of subjects will undergo Re-TURBT or cystoscopy 10-12 weeks after surgery to compare the tumor-free residual rates and adverse events between the two groups., conditionsModule conditions: Bladder Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 190, type: ESTIMATED, armsInterventionsModule interventions name: Transurethral cryoablation, interventions name: Transurethral resection of bladder tumor, interventions name: Bcg Intravesical, outcomesModule primaryOutcomes measure: Tumor residual rate, secondaryOutcomes measure: Recurrence, secondaryOutcomes measure: Progression, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323993, orgStudyIdInfo id: 2021-115, briefTitle: The Effect of Different Window-preparation Approaches on the Clinical Outcomes of Lateral Sinus Floor Elevation, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2022-05-01, completionDateStruct date: 2023-06-15, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: The Dental Hospital of Zhejiang University School of Medicine, class: OTHER, descriptionModule briefSummary: This study retrospectively evaluated the effect of two different lateral window preparation techniques on peri-implant bone augmentation for patients who underwent lateral sinus floor elevation with simultaneous implant placement using two-dimensional and three-dimensional radiographic results, with special emphasis placed on the stability of the graft material after surgery., conditionsModule conditions: Dental Implantation, conditions: Cone-Beam Computed Tomography, conditions: Surgical Procedure, Unspecified, conditions: Maxillary Sinus Floor Augmentation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 34, type: ACTUAL, armsInterventionsModule interventions name: Piezoelectric osteotomy, outcomesModule primaryOutcomes measure: Apical bone height, primaryOutcomes measure: Endo-sinus bone gain, primaryOutcomes measure: Palatal bone height, primaryOutcomes measure: Buccal bone height, primaryOutcomes measure: Augmentation volume, secondaryOutcomes measure: Perforation incidence, secondaryOutcomes measure: Early implant loss, secondaryOutcomes measure: Lateral window length, secondaryOutcomes measure: Lateral bone length, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06323954, orgStudyIdInfo id: H24110, briefTitle: tVNS During Motor Training in Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Georgia Institute of Technology, class: OTHER, collaborators name: University of Florida, descriptionModule briefSummary: The goal of this study is to learn about the effect of applying transcutaneous vagus nerve stimulation (tVNS) during motor training on motor learning in older adults. The main question it aims to answer is whether applying tVNS after successful motor trials (post-success tVNS) will facilitate the rate of motor learning. Participants will be randomly assigned to tVNS or sham group and receive tVNS or sham, respectively, at the outer ear during finger control training sessions. Finger control performance will be tested before and after the training sessions without outer ear stimulation., conditionsModule conditions: Older Adults, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: tVNS stimulation, interventions name: Sham stimulation, outcomesModule primaryOutcomes measure: Rate of error reduction, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 84 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Human Neuromuscular Physiology Lab, city: Atlanta, state: Georgia, zip: 30332, country: United States, contacts name: Minoru Shinohara, Ph.D., role: CONTACT, phone: 404-894-1030, email: shinohara@gatech.edu, contacts name: Minoru Shinohara, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06323941, orgStudyIdInfo id: UV0003, briefTitle: Motor Imagery and Isometric Exercises on Pelvic Floor Sensorimotor Condition, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-14, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: University of Valencia, class: OTHER, descriptionModule briefSummary: Mental practice (both in isolation and also in combination with real practice) has been shown to improve somatosensory and motor variables but so far no study has taken it into the study of women's health. Through the present study the investigators want to offer some interesting data regarding the effectiveness of mental practice combined with physical practice., conditionsModule conditions: Isometric Exercise, conditions: Motor Imagery, conditions: Women's Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Motor Imagery plus therapeutic exercise, interventions name: Therapeutic exercises, outcomesModule primaryOutcomes measure: Skin conductance (for asessing electrodermal activity), secondaryOutcomes measure: Algometry for assessing pressure pain thresholds (Pain sensitivity), secondaryOutcomes measure: maximal pelvic floor muscle strength (measured in grams and with the phenix device), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ferran Cuenca Martínez, city: Valencia, zip: 46017, country: Spain, geoPoint lat: 39.46975, lon: -0.37739, hasResults: False
protocolSection identificationModule nctId: NCT06323928, orgStudyIdInfo id: 20297A, secondaryIdInfos id: 2023-508821-28-00, type: OTHER, domain: EU Trial, briefTitle: A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments, acronym: PROCEED, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: H. Lundbeck A/S, class: INDUSTRY, descriptionModule briefSummary: The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 2 to 4 other available medications to prevent their migraines, but these medications have not helped them., conditionsModule conditions: Migraine, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 498, type: ESTIMATED, armsInterventionsModule interventions name: Lu AG09222, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change From Baseline in the Number of Monthly Migraine Days (MMDs), secondaryOutcomes measure: Change From Baseline in MMDs, secondaryOutcomes measure: Percentage of Participants With ≥50% Reduction From Baseline in MMDs, secondaryOutcomes measure: Percentage of Participants With ≥75% Reduction From Baseline in MMDs, secondaryOutcomes measure: Change from Baseline in the Number of Monthly Headache Days, secondaryOutcomes measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs), secondaryOutcomes measure: Number of Participants with Anti-drug Antibodies (ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Accellacare of Charleston, status: RECRUITING, city: Mount Pleasant, state: South Carolina, zip: 29464, country: United States, geoPoint lat: 32.79407, lon: -79.86259, hasResults: False
protocolSection identificationModule nctId: NCT06323915, orgStudyIdInfo id: 2020_03_C3M, briefTitle: Comparative Study of 3 Multifocal Intraocular Lenses in Murcia, acronym: C3M, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-04-20, primaryCompletionDateStruct date: 2025-06-20, completionDateStruct date: 2025-09-20, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Cristalens Industrie, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to compare the performance of 3 intraocular lenses (IOLs): FineVision (comparator), ARTIS SYMBIOSE (study lenses), and Tecnis Synergy (comparator) through binocular distance-corrected defocus curve.This main objective will be to show superiority of the ARTIS SYMBIOSE system through binocular distance-corrected defocus curve.The patient population to be included is patient suffering from cataract who requires cataract surgery procedure that meet the inclusion and non-inclusion criteria and provide written informed consent.Participants will attend a total of 5 study visits: 1 preoperative visit, 1 surgery visit and 3 postoperative visits., conditionsModule conditions: Cataract, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: intraocular lens implantation in cataract surgery, outcomesModule primaryOutcomes measure: defocus curve comparison, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vista Clinic Ircovision Murcia, status: RECRUITING, city: Murcia, zip: 30008, country: Spain, contacts name: Juan Zapata, role: CONTACT, phone: +34 968 27 17 35, email: juanf.zapata.diaz@gmail.com, geoPoint lat: 37.98704, lon: -1.13004, hasResults: False
protocolSection identificationModule nctId: NCT06323902, orgStudyIdInfo id: PT-CO39, briefTitle: Autologous Platelet-rich Plasma as a Treatment for Macular Holes, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-10-25, primaryCompletionDateStruct date: 2023-06-08, completionDateStruct date: 2024-02-29, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Clinica Oftalmologica Paredes, class: OTHER, descriptionModule briefSummary: For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally., conditionsModule conditions: Macular Holes, conditions: Macular Hole of Left Eye (Disorder), conditions: Macular Hole of Right Eye (Disorder), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 13, type: ACTUAL, armsInterventionsModule interventions name: Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation, outcomesModule primaryOutcomes measure: Macular hole closure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinica Ofalmologica Paredes, city: Pasto, state: Nariño, zip: 520002, country: Colombia, geoPoint lat: 1.21361, lon: -77.28111, hasResults: False
protocolSection identificationModule nctId: NCT06323889, orgStudyIdInfo id: LIMITFOOD2, briefTitle: Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults, acronym: LIMITFOOD2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2027-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Zurich, class: OTHER, descriptionModule briefSummary: LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling., conditionsModule conditions: Intermittent Fasting, conditions: Obesity, conditions: Time Restricted Eating, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Modified Alternate Day Fasting, interventions name: Time-Restricted Eating, interventions name: Weight-loss counseling, outcomesModule primaryOutcomes measure: Fat Volume, secondaryOutcomes measure: Distribution of fat volume, secondaryOutcomes measure: Concentration of Leptin, secondaryOutcomes measure: Changes in Insulin Sensitivity, secondaryOutcomes measure: Changes in Fasting Lipids, secondaryOutcomes measure: Changes in Inflammatory Markers, secondaryOutcomes measure: Free triiodothyronine (fT3), otherOutcomes measure: Correlation of longitudinally measured parameters, otherOutcomes measure: Serum Metabolomics, otherOutcomes measure: Genetic Analysis, otherOutcomes measure: LDL Particle Size, otherOutcomes measure: Fecal Microbiome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Endocrinology, Diabetology and Clinical Nutrition, city: Zürich, zip: 8091, country: Switzerland, geoPoint lat: 47.36667, lon: 8.54999, hasResults: False
protocolSection identificationModule nctId: NCT06323876, orgStudyIdInfo id: HSR301252, secondaryIdInfos id: R01HL171918, type: NIH, link: https://reporter.nih.gov/quickSearch/R01HL171918, briefTitle: The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-05, completionDateStruct date: 2029-05, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of Virginia, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available., conditionsModule conditions: Idiopathic Pulmonary Fibrosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: HRCT, interventions name: Blood Draw, outcomesModule primaryOutcomes measure: Derivation of DTA in IPF only cases from the PFF-PR and its associations with disease severity and outcomes., primaryOutcomes measure: Determine whether known IPF-risk genetic variants are associated with DTA score., primaryOutcomes measure: Identify novel genetic variants that associate with DTA score progression., primaryOutcomes measure: Determine if DTA or any constituent radiomic features correlate with select plasma proteins., primaryOutcomes measure: Determine if DTA or any of constituent radiomic features correlate with transcriptomic, primaryOutcomes measure: Determine the best combination of markers (DTA, proteins and transcriptome) for machine learning algorithms for AUC evaluation of ROCs on all 3 cohorts., secondaryOutcomes measure: Determine associations of changes in DTA scores with 12-month changes in FVC and DLCO., secondaryOutcomes measure: Determine associations of changes in DTA scores with drug treatment (i.e., antifibrotics), eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 101 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323863, orgStudyIdInfo id: N°4-RCB/EUDRACT, briefTitle: Ultra-high Resolution CT: the End of Stapes Prosthesis Measurement Misestimation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Central Hospital, Nancy, France, class: OTHER, descriptionModule briefSummary: Actual CT scanners overestimate stapes piston size, and do not represent a valuable technique for their follow-up, especially in case of complication. Ultra-high resolution has not yet been evaluated in this setting., conditionsModule conditions: Otosclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: stapedectomy, interventions name: ultra high resolution CT, outcomesModule primaryOutcomes measure: length, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chu Nancy, city: Nancy, zip: 54000, country: France, contacts name: romain gillet, md, role: CONTACT, phone: 00383851811, email: r.gillet@chru-nancy.fr, geoPoint lat: 48.68439, lon: 6.18496, hasResults: False